Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxifloxacin Hydrochloride

FDA-approved product (tablet, oral), marketed as Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Moxeza and 3 more.

Registered studies
50+
Lab records
54
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxifloxacin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Eye infection
  • Infection
  • Pneumonia
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA14; WHO ATC S01AE07

Repurposing investigation

Moxifloxacin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 28 of 28 lab records
  • M. tuberculosis: measured active in 24 of 25 lab records
Open Moxifloxacin Hydrochloride in ChEMBL Registered studies below
Show the 54 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxifloxacin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Thorough Corrected QT Interval Trial

    NCT02073084 · start 2014-01

    Registered record
    Registry ID
    NCT02073084
    Conditions
    Dyslipidemia
    Interventions
    K-877 Low Dose; Moxifloxacin; Placebo; K-877 High Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01
    Completion
    Not recorded
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionK-877 Low Dose; Moxifloxacin; Placebo; K-877 High Dose
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

    NCT01860703 · start 2012-11

    Registered record
    Registry ID
    NCT01860703
    Conditions
    Prolonged QTc Interval
    Interventions
    Deferiprone; deferiprone matching placebo tablets; moxifloxacin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlonged QTc Interval
    InterventionDeferiprone; deferiprone matching placebo tablets; moxifloxacin; placebo
    PhasePhase 4
    Registry statusCompleted

  • This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

    NCT01702376 · start 2012-10-03

    Registered record
    Registry ID
    NCT01702376
    Conditions
    Obstetric Labour, Premature
    Interventions
    Retosiban 100 mg; Retosiban 800 mg; Placebo; Moxifloxacin 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10-03
    Completion
    2013-01-14
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstetric Labour, Premature
    InterventionRetosiban 100 mg; Retosiban 800 mg; Placebo; Moxifloxacin 400 mg
    PhasePhase 1
    Registry statusCompleted

  • Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

    NCT02206204 · start 2012-06

    Registered record
    Registry ID
    NCT02206204
    Conditions
    Cardiodynamics; Safety; Tolerability; Pharmacokinetics
    Interventions
    selexipag; placebo for selexipag; moxifloxacin; moxifloxacin-matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2012-11
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiodynamics; Safety; Tolerability; Pharmacokinetics
    Interventionselexipag; placebo for selexipag; moxifloxacin; moxifloxacin-matching placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

    NCT01859702 · start 2012-04

    Registered record
    Registry ID
    NCT01859702
    Conditions
    Cataract
    Interventions
    Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionMoxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

    NCT01287793 · start 2011-01

    Registered record
    Registry ID
    NCT01287793
    Conditions
    Healthy
    Interventions
    tigecycline; tigecycline; moxifloxacin; 100 mL 0.9% Sodium Chloride intravenous; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontigecycline; tigecycline; moxifloxacin; 100 mL 0.9% Sodium Chloride intravenous +1 more
    PhasePhase 1
    Registry statusCompleted

  • Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

    NCT01209026 · start 2010-06-23

    Registered record
    Registry ID
    NCT01209026
    Conditions
    Asthma
    Interventions
    Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination; Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination; Placebo Inhaler; Moxifloxacin 400mg; Moxifloxacin placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06-23
    Completion
    2011-01-04
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone furoate (200 mcg)/GW642444 (25mcg) combination; Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination; Placebo Inhaler; Moxifloxacin 400mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • CAEB071 Thorough QTc Study in Healthy Volunteers

    NCT01594255 · start 2009-07

    Registered record
    Registry ID
    NCT01594255
    Conditions
    Healthy
    Interventions
    sotrastaurin; sotrastaurin; placebo to sotrastaurin; Avelox
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionsotrastaurin; sotrastaurin; placebo to sotrastaurin; Avelox
    PhasePhase 1
    Registry statusCompleted

  • Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess

    NCT00895089 · start 2009-05

    Registered record
    Registry ID
    NCT00895089
    Conditions
    Liver Abscess
    Interventions
    Moxifloxacin (Avelox); ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Abscess
    InterventionMoxifloxacin (Avelox); ceftriaxone
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

    NCT01613040 · start 2009-01

    Registered record
    Registry ID
    NCT01613040
    Conditions
    Healthy Volunteer
    Interventions
    Moxifloxacin; Moxifloxacin; RO4917838; RO4917838; RO4917838 placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-07
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionMoxifloxacin; Moxifloxacin; RO4917838; RO4917838 +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

    NCT00789568 · start 2008-10

    Registered record
    Registry ID
    NCT00789568
    Conditions
    Phenylketonuria
    Interventions
    sapropterin dihydrochloride; Moxifloxacin; Moxifloxacin placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhenylketonuria
    Interventionsapropterin dihydrochloride; Moxifloxacin; Moxifloxacin placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

    NCT00675701 · start 2008-05

    Registered record
    Registry ID
    NCT00675701
    Conditions
    Healthy
    Interventions
    placebo; lixivaptan; moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-10
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionplacebo; lixivaptan; moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

    NCT00703313 · start 2008-05

    Registered record
    Registry ID
    NCT00703313
    Conditions
    Healthy
    Interventions
    1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

    NCT00439972 · start 2007-02

    Registered record
    Registry ID
    NCT00439972
    Conditions
    Contraception
    Interventions
    Ortho-Cyclen (R); Ortho Evra (R); extended use of Ortho Evra (R)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2011-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionOrtho-Cyclen (R); Ortho Evra (R); extended use of Ortho Evra (R)
    PhasePhase 2
    Registry statusUnknown

  • Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

    NCT00411073 · start 2006-12

    Registered record
    Registry ID
    NCT00411073
    Conditions
    Atherosclerosis
    Interventions
    Darapladib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-12
    Completion
    Not recorded
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis
    InterventionDarapladib
    PhasePhase 1
    Registry statusCompleted